NVO
Novo Nordisk A/S
NYSE: NVO · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$46.40
-1.81% today
Updated 2026-06-05
Market cap
$194.70B
P/E ratio
10.32
P/S ratio
0.59x
EPS (TTM)
$4.26
Dividend yield
4.10%
52W range
$35 – $75
Volume
15.8M
WallStSmart proprietary scores
73
out of 100
Grade: B
Buy
Investment rating
9.3
Growth
A+5.0
Quality
C+10.0
Profitability
A+5.7
Valuation
C+3/9
Piotroski F-Score
Weak
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$51.00
+9.91%
12-Month target
$36.86
-20.56%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy4 Buy9 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 37.20% — above average
+ ROE 60.06% — strong efficiency
+ Free cash flow $12.04B — positive
+ Revenue growth 24.00% QoQ
Risks
- Piotroski 3/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $176.95B | $232.26B | $290.40B | $309.06B | $327.80B | $296.9B |
| Net income | $55.52B | $83.68B | $100.99B | $102.43B | $48.56B | — |
| EPS | — | — | — | — | $4.26 | $22.12 |
| Free cash flow | $64.13B | $70.01B | $69.66B | $28.99B | $12.04B | — |
| Profit margin | 31.38% | 36.03% | 34.78% | 33.14% | 37.20% | — |
Peer comparison
Smart narrative
Novo Nordisk A/S trades at $46.40. representing a P/E of 10.32x trailing earnings. Our Smart Value Score of 73/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.13, it sits in the grey zone. TTM revenue stands at $327.80B. with profit margins at 37.20%.
Frequently asked questions
What is Novo Nordisk A/S's stock price?
Novo Nordisk A/S (NVO) trades at $46.40, on a P/E of 10.3x and a P/S of 0.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Novo Nordisk A/S overvalued?
Novo Nordisk A/S carries a Smart Value Score of 73/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Novo Nordisk A/S (NVO)?
The 12-month analyst consensus target is $51.00, about 9.9% above the current $46.40. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of NVO by 2030?
Our research-backed model puts the 2030 base case at $1,065.02, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Novo Nordisk A/S's revenue?
Novo Nordisk A/S's trailing twelve-month revenue is $327.80B, and our model projects it reaching about $388.20B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Novo Nordisk A/S's Altman Z-Score is 2.13, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.59x
ROE60.06%
Beta0.35
50D MA$42.26
200D MA$48.46
Shares out3.35B
Float3.19B
Short ratio—
Avg volume15.8M
Performance
1 week+0.00%
1 month-3.98%
3 months+15.19%
YTD-15.57%
1 year—
3 years—
5 years—